The urgency of the problem of osteoarthritis (OA) high in Russia and around the world. Over the last 40 years in the world recorded an increase in the incidence of OA in 9 times. Only in Russia there are about 15 million patients with OA. According to statistics, OA most often among other rheumatic diseases leads to disruption of the functional capacity of the musculoskeletal system and is the second leading cause of temporary and persistent loss of working capacity, significantly impairing patients ‘ quality of life.
Modern algorithms for the treatment of OA summarize all used non-pharmacological and pharmacological techniques and propose a consistent scheme for incorporating a variety of therapy tools, among which the main emphasis is on the use of symptom-modifying agents, in particular drugs pathogenetic therapy of chondroprotectors.
Chondroprotectors Among the largest evidence base collected in respect of chondroitin sulfate (CS) and glucosamine sulfate. Chondroitin sulfate is one of the basic components of connective tissue, part of bone, cartilage, tendons, ligaments, provides a mechanical joint function, in particular resistance to compression. Because OA is associated with a local deficiency of cholesterol, its use in OA is pathogenetically grounded. Cholesterol is absorbed intact or in the form of components, provides additional substrate for the formation of healthy joint matrix. In addition, KHS promotes water preservation in the thickness of the cartilage, and the anti-inflammatory and analgesic effect of CH reduces the need to use anti-inflammatory drugs.
Reference substance of the European Pharmacopoeia, which is the basis for the production of chondroprotectors in the EU, is cholesterol produced from animal tissue. This year to take advantage of the drug, manufactured according to European standards, can and Russian patients: in Russia, a new injectable cholesterol made in Europe, made from EU certified raw materials.
This dosage form is intended for the treatment of degenerative-dystrophic diseases of joints and spine (OA of the peripheral joints, intervertebral OA and low back pain).
The drug helps to reduce degenerative changes in the cartilage of joints, stimulates biosynthesis of glycosaminoglycans. Chondroitin sulfate slows down the process of degeneration of cartilage, stimulates the regeneration of articular cartilage, its action is directed on restoration of the joint capsule and cartilage surfaces of the joints, which helps to slow the progression of OA and facilitates its symptoms.
Registration of a new injectable chondroitin sulfate company World Medicine (TM “Dragstop”) on the Russian market opens new prospects of therapy and improve the quality of life of patients with OA.